The default mode network and cognition in Parkinson's disease: A multimodal resting-state network approach

Involvement of the default mode network (DMN) in cognitive symptoms of Parkinson's disease (PD) has been reported by resting-state functional MRI (rsfMRI) studies. However, the relation to metabolic measures obtained by [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) is largely...

Full description

Bibliographic Details
Main Authors: Drzezga, A. (Author), Eggers, C. (Author), Freigang, J. (Author), Greuel, A. (Author), Hammes, J. (Author), Maier, F. (Author), Ruppert, M.C (Author), Tahmasian, M. (Author), Timmermann, L. (Author), Tittgemeyer, M. (Author), van Eimeren, T. (Author)
Format: Article
Language:English
Published: John Wiley and Sons Inc 2021
Subjects:
Online Access:View Fulltext in Publisher
LEADER 04535nam a2200949Ia 4500
001 10.1002-hbm.25393
008 220427s2021 CNT 000 0 und d
020 |a 10659471 (ISSN) 
245 1 0 |a The default mode network and cognition in Parkinson's disease: A multimodal resting-state network approach 
260 0 |b John Wiley and Sons Inc  |c 2021 
856 |z View Fulltext in Publisher  |u https://doi.org/10.1002/hbm.25393 
520 3 |a Involvement of the default mode network (DMN) in cognitive symptoms of Parkinson's disease (PD) has been reported by resting-state functional MRI (rsfMRI) studies. However, the relation to metabolic measures obtained by [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) is largely unknown. We applied multimodal resting-state network analysis to clarify the association between intrinsic metabolic and functional connectivity abnormalities within the DMN and their significance for cognitive symptoms in PD. PD patients were classified into normal cognition (n = 36) and mild cognitive impairment (MCI; n = 12). The DMN was identified by applying an independent component analysis to FDG-PET and rsfMRI data of a matched subset (16 controls and 16 PD patients) of the total cohort. Besides metabolic activity, metabolic and functional connectivity within the DMN were compared between the patients' groups and healthy controls (n = 16). Glucose metabolism was significantly reduced in all DMN nodes in both patient groups compared to controls, with the lowest uptake in PD-MCI (p <.05). Increased metabolic and functional connectivity along fronto-parietal connections was identified in PD-MCI patients compared to controls and unimpaired patients. Functional connectivity negatively correlated with cognitive composite z-scores in patients (r = −.43, p =.005). The current study clarifies the commonalities of metabolic and hemodynamic measures of brain network activity and their individual significance for cognitive symptoms in PD, highlighting the added value of multimodal resting-state network approaches for identifying prospective biomarkers. © 2021 The Authors. Human Brain Mapping published by Wiley Periodicals LLC. 
650 0 4 |a [18F]-FDG-PET 
650 0 4 |a aged 
650 0 4 |a Aged 
650 0 4 |a Article 
650 0 4 |a brain cortex 
650 0 4 |a Cerebral Cortex 
650 0 4 |a cognition 
650 0 4 |a cognitive defect 
650 0 4 |a Cognitive Dysfunction 
650 0 4 |a comparative study 
650 0 4 |a complication 
650 0 4 |a connectome 
650 0 4 |a Connectome 
650 0 4 |a controlled study 
650 0 4 |a data analysis software 
650 0 4 |a default mode network 
650 0 4 |a default mode network 
650 0 4 |a Default Mode Network 
650 0 4 |a diagnostic imaging 
650 0 4 |a dopamine receptor stimulating agent 
650 0 4 |a female 
650 0 4 |a Female 
650 0 4 |a fluorodeoxyglucose 
650 0 4 |a frontoparietal network 
650 0 4 |a functional connectivity 
650 0 4 |a functional magnetic resonance imaging 
650 0 4 |a glucose 
650 0 4 |a glucose metabolism 
650 0 4 |a hemodynamics 
650 0 4 |a human 
650 0 4 |a Humans 
650 0 4 |a levodopa 
650 0 4 |a Magnetic Resonance Imaging 
650 0 4 |a major clinical study 
650 0 4 |a male 
650 0 4 |a Male 
650 0 4 |a metabolic covariance 
650 0 4 |a metabolic parameters 
650 0 4 |a metabolism 
650 0 4 |a middle aged 
650 0 4 |a Middle Aged 
650 0 4 |a mild cognitive impairment 
650 0 4 |a mild cognitive impairment 
650 0 4 |a multimodal imaging 
650 0 4 |a multimodal imaging 
650 0 4 |a Multimodal Imaging 
650 0 4 |a nuclear magnetic resonance imaging 
650 0 4 |a Parkinson disease 
650 0 4 |a Parkinson disease 
650 0 4 |a Parkinson Disease 
650 0 4 |a Parkinson's disease 
650 0 4 |a pathophysiology 
650 0 4 |a positron emission tomography 
650 0 4 |a positron emission tomography 
650 0 4 |a Positron-Emission Tomography 
650 0 4 |a priority journal 
650 0 4 |a resting state network 
650 0 4 |a resting-state fMRI 
700 1 |a Drzezga, A.  |e author 
700 1 |a Eggers, C.  |e author 
700 1 |a Freigang, J.  |e author 
700 1 |a Greuel, A.  |e author 
700 1 |a Hammes, J.  |e author 
700 1 |a Maier, F.  |e author 
700 1 |a Ruppert, M.C.  |e author 
700 1 |a Tahmasian, M.  |e author 
700 1 |a Timmermann, L.  |e author 
700 1 |a Tittgemeyer, M.  |e author 
700 1 |a van Eimeren, T.  |e author 
773 |t Human Brain Mapping